Dyadic International Inc, DE Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $3.8M+8.8% YoYTTM through 30 Jun 2026
Net Income -$7.6MTTM through 30 Jun 2026
Free Cash Flow -$7.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 24.9% |
| Operating Margin | -232.7% |
| Net Margin | -200.5% |
Returns
-74.0%ROA
Balance Sheet Health
Debt / Equity1.94x
Current Ratio1.14x
Net Debt-$2.2Mnet cash position
Cash & Equivalents$1.4M
Quality Metrics
Altman Z-Score-22.51
Piotroski F-Score2 / 9
FCF Margin-194.7%
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $3.1M
Diluted EPS-$0.21TTMFY2025: $-0.23
Dividend
No dividend
Capital Allocation
R&D Spend$1.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Alternative Proteins | View detailsCommercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals and expanded strategic collaborations with Fermbox Bio and BRIG Bio are expected to drive product revenue growth in 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.